Top

Published in:

Open Access 01-04-2019 | Educational Review

Measurement of iron status in chronic kidney disease

Author: Wesley Hayes

Published in: Pediatric Nephrology | Issue 4/2019

Abstract

Anemia is a common complication of chronic kidney disease (CKD) in children, and dysregulation of iron homeostasis plays a central role in its pathogenesis. Optimizing iron status is a prerequisite for effective treatment of anemia. Insufficient iron can lead to inappropriate escalation of the erythropoiesis-stimulating agent (ESA) dose, which is associated with adverse outcomes. Excess iron supplementation also has negative sequelae including free radical tissue damage and increased risk of systemic infection. Notwithstanding the importance of optimizing bioavailable iron for erythropoiesis for children with advanced CKD, achieving this remains challenging for pediatric nephrologists due to the historical lack of practical and robust measures of iron status. In recent years, novel techniques have come to the fore to facilitate accurate and practical assessment of iron balance. These measures are the focus of this review, with emphasis on their relevance to the pediatric CKD population.

Atkinson MA, Martz K, Warady BA, Neu AM (2010) Risk for anemia in pediatric chronic kidney disease patients: a report of NAPRTCS. Pediatr Nephrol 25:1699–1706CrossRefPubMed

Staples AO, Wong CS, Smith JM, Gipson DS, Filler G, Warady BA, Martz K, Greenbaum LA (2009) Anemia and risk of hospitalization in pediatric chronic kidney disease. Clin J Am Soc Nephrol 4:48–56CrossRefPubMedPubMedCentral

Atkinson MA, Warady BA (2017) Anemia in chronic kidney disease. Pediatr Nephrol 33:227–238CrossRefPubMed

Atkinson MA, Furth SL (2011) Anemia in children with chronic kidney disease. Nat Rev Nephrol 7:635–641CrossRefPubMedPubMedCentral

Singh AK, Szczech L, Tang KL, Barnhart H, Sapp S, Wolfson M, Reddan D, Investigators C (2006) Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 355:2085–2098CrossRefPubMed

Pfeffer MA, Burdmann EA, Chen CY, Cooper ME, de Zeeuw D, Eckardt KU, Feyzi JM, Ivanovich P, Kewalramani R, Levey AS, Lewis EF, McGill JB, McMurray JJ, Parfrey P, Parving HH, Remuzzi G, Singh AK, Solomon SD, Toto R, Investigators T (2009) A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 361:2019–2032CrossRefPubMed

Borzych-Duzalka D, Bilginer Y, Ha IS, Bak M, Rees L, Cano F, Munarriz RL, Chua A, Pesle S, Emre S, Urzykowska A, Quiroz L, Ruscasso JD, White C, Pape L, Ramela V, Printza N, Vogel A, Kuzmanovska D, Simkova E, Muller-Wiefel DE, Sander A, Warady BA, Schaefer F, International Pediatric Peritoneal Dialysis Network R (2013) Management of anemia in children receiving chronic peritoneal dialysis. J Am Soc Nephrol 24:665–676CrossRefPubMedPubMedCentral

Lestz RM, Fivush BA, Atkinson MA (2014) Association of higher erythropoiesis stimulating agent dose and mortality in children on dialysis. Pediatr Nephrol 29:2021–2028CrossRefPubMedPubMedCentral

Cichota LC, Bochi GV, Tatsch E, Torbitz VD, Agnol PR, Zanardo JC, Barbisan F, da Cruz IB, Vaucher Rde A, Moresco RN (2015) Circulating double-stranded DNA in plasma of hemodialysis patients and its association with iron stores. Clin Lab 61:985–990CrossRefPubMed

10.

Nakanishi T, Kuragano T, Nanami M, Hasuike Y (2016) Iron localization and infectious disease in chronic kidney disease patients. Am J Nephrol 43:237–244CrossRefPubMed

11.

Varas J, Ramos R, Aljama P, Perez-Garcia R, Moreso F, Pinedo M, Ignacio Merello J, Stuard S, Canaud B, Martin-Malo A, Group ORD (2018) Relationships between iron dose, hospitalizations and mortality in incident haemodialysis patients: a propensity-score matched approach. Nephrol Dial Transplant 33:160–170CrossRefPubMed

12.

Ganz T (2013) Systemic iron homeostasis. Physiol Rev 93:1721–1741CrossRefPubMed

13.

Finch C (1994) Regulators of iron balance in humans. Blood 84:1697–1702PubMed

14.

Abboud S, Haile DJ (2000) A novel mammalian iron-regulated protein involved in intracellular iron metabolism. J Biol Chem 275:19906–19912CrossRefPubMed

15.

Nemeth E, Tuttle MS, Powelson J, Vaughn MB, Donovan A, Ward DM, Ganz T, Kaplan J (2004) Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science 306:2090–2093CrossRefPubMed

16.

Park CH, Valore EV, Waring AJ, Ganz T (2001) Hepcidin, a urinary antimicrobial peptide synthesized in the liver. J Biol Chem 276:7806–7810CrossRefPubMed

17.

Zaritsky J, Young B, Gales B, Wang HJ, Rastogi A, Westerman M, Nemeth E, Ganz T, Salusky IB (2010) Reduction of serum hepcidin by hemodialysis in pediatric and adult patients. Clin J Am Soc Nephrol 5:1010–1014CrossRefPubMedPubMedCentral

18.

Malyszko J, Malyszko JS, Mysliwiec M (2009) Hyporesponsiveness to erythropoietin therapy in hemodialyzed patients: potential role of prohepcidin, hepcidin, and inflammation. Ren Fail 31:544–548CrossRefPubMed

19.

Kdoqi, National Kidney F (2006) KDOQI clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease. Am J Kidney Dis 47:S11–S145CrossRef

20.

Kidney Disease: Improving Global Outcomes (KDIGO) Anemia Work Group (2012) KDIGO clinical practice guideline for anemia in chronic kidney disease. Kidney Int Suppl 2:279–335CrossRef

21.

Van Wyck DB, Alcorn H Jr, Gupta R (2010) Analytical and biological variation in measures of anemia and iron status in patients treated with maintenance hemodialysis. Am J Kidney Dis 56:540–546CrossRefPubMed

22.

Ford BA, Coyne DW, Eby CS, Scott MG (2009) Variability of ferritin measurements in chronic kidney disease; implications for iron management. Kidney Int 75:104–110CrossRefPubMed

23.

(NICE) NIfHaCE (2015) Anaemia management in chronic kidney disease: update 2015. NICE guideline 8 https://www.nice.org.uk/guidance/ng8/chapter/1-recommendations

24.

Silverstein DM (2009) Inflammation in chronic kidney disease: role in the progression of renal and cardiovascular disease. Pediatr Nephrol 24:1445–1452CrossRefPubMed

25.

Canpolat N, Caliskan S, Sever L, Tasdemir M, Ekmekci OB, Pehlivan G, Shroff R (2013) Malnutrition and its association with inflammation and vascular disease in children on maintenance dialysis. Pediatr Nephrol 28:2149–2156CrossRefPubMed

26.

Sylvestre LC, Fonseca KP, Stinghen AE, Pereira AM, Meneses RP, Pecoits-Filho R (2007) The malnutrition and inflammation axis in pediatric patients with chronic kidney disease. Pediatr Nephrol 22:864–873CrossRefPubMed

27.

Hayes WN, Watson AR, Callaghan N, Wright E, Stefanidis CJ, European Pediatric Dialysis Working G (2012) Vascular access: choice and complications in European paediatric haemodialysis units. Pediatr Nephrol 27:999–1004CrossRefPubMed

28.

Sethna CB, Bryant K, Munshi R, Warady BA, Richardson T, Lawlor J, Newland JG, Neu A, Investigators S (2016) Risk factors for and outcomes of catheter-associated peritonitis in children: the SCOPE collaborative. Clin J Am Soc Nephrol 11:1590–1596CrossRefPubMedPubMedCentral

29.

Sen ES, Steward CG, Ramanan AV (2017) Diagnosing haemophagocytic syndrome. Arch Dis Child 102:279–284CrossRefPubMed

30.

Kalantar-Zadeh K, Rodriguez RA, Humphreys MH (2004) Association between serum ferritin and measures of inflammation, nutrition and iron in haemodialysis patients. Nephrol Dial Transplant 19:141–149CrossRefPubMed

31.

Kalantar-Zadeh K, Kalantar-Zadeh K, Lee GH (2006) The fascinating but deceptive ferritin: to measure it or not to measure it in chronic kidney disease? Clin J Am Soc Nephrol 1(Suppl 1):S9–S18CrossRefPubMed

32.

Kalantar-Zadeh K, Kleiner M, Dunne E, Ahern K, Nelson M, Koslowe R, Luft FC (1998) Total iron-binding capacity-estimated transferrin correlates with the nutritional subjective global assessment in hemodialysis patients. Am J Kidney Dis 31:263–272CrossRefPubMed

33.

Kalantar-Zadeh K, Ikizler TA, Block G, Avram MM, Kopple JD (2003) Malnutrition-inflammation complex syndrome in dialysis patients: causes and consequences. Am J Kidney Dis 42:864–881CrossRefPubMed

34.

Silber JH, Evans AE, Fridman M (1991) Models to predict outcome from childhood neuroblastoma: the role of serum ferritin and tumor histology. Cancer Res 51:1426–1433PubMed

35.

Blatt J, Huntley D, Eagon PK (1990) Synthesis of ferritin by neuroblastoma. Cancer Biochem Biophys 11:169–176PubMed

36.

Hann HW, Lange B, Stahlhut MW, McGlynn KA (1990) Prognostic importance of serum transferrin and ferritin in childhood Hodgkin's disease. Cancer 66:313–316CrossRefPubMed

37.

Macdougall IC, Cavill I, Hulme B, Bain B, McGregor E, McKay P, Sanders E, Coles GA, Williams JD (1992) Detection of functional iron deficiency during erythropoietin treatment: a new approach. BMJ 304:225–226CrossRefPubMedPubMedCentral

38.

Mast AE, Blinder MA, Lu Q, Flax S, Dietzen DJ (2002) Clinical utility of the reticulocyte hemoglobin content in the diagnosis of iron deficiency. Blood 99:1489–1491CrossRefPubMed

39.

Chuang CL, Liu RS, Wei YH, Huang TP, Tarng DC (2003) Early prediction of response to intravenous iron supplementation by reticulocyte haemoglobin content and high-fluorescence reticulocyte count in haemodialysis patients. Nephrol Dial Transplant 18:370–377CrossRefPubMed

40.

Urrechaga E, Boveda O, Aguayo FJ, de la Hera P, Munoz RI, Gallardo I, Escanero JF (2016) Percentage of hypochromic erythrocytes and reticulocyte hemoglobin equivalent predictors of response to intravenous iron in hemodialysis patients. Int J Lab Hematol 38:360–365CrossRefPubMed

41.

Fishbane S, Shapiro W, Dutka P, Valenzuela OF, Faubert J (2001) A randomized trial of iron deficiency testing strategies in hemodialysis patients. Kidney Int 60:2406–2411CrossRefPubMed

42.

Kaneko Y, Miyazaki S, Hirasawa Y, Gejyo F, Suzuki M (2003) Transferrin saturation versus reticulocyte hemoglobin content for iron deficiency in Japanese hemodialysis patients. Kidney Int 63:1086–1093CrossRefPubMed

43.

Canals C, Remacha AF, Sarda MP, Piazuelo JM, Royo MT, Romero MA (2005) Clinical utility of the new Sysmex XE 2100 parameter-reticulocyte hemoglobin equivalent - in the diagnosis of anemia. Haematologica 90:1133–1134PubMed

44.

Lorenz L, Arand J, Buchner K, Wacker-Gussmann A, Peter A, Poets CF, Franz AR (2015) Reticulocyte haemoglobin content as a marker of iron deficiency. Arch Dis Child Fetal Neonatal Ed 100:F198–F202CrossRefPubMed

45.

Parodi E, Giraudo MT, Ricceri F, Aurucci ML, Mazzone R, Ramenghi U (2016) Absolute reticulocyte count and reticulocyte hemoglobin content as predictors of early response to exclusive oral iron in children with iron deficiency anemia. Anemia 2016:7345835CrossRefPubMedPubMedCentral

46.

Syed S, Kugathasan S, Kumar A, Prince J, Schoen BT, McCracken C, Ziegler TR, Suchdev PS (2017) Use of reticulocyte hemoglobin content in the assessment of iron deficiency in children with inflammatory bowel disease. J Pediatr Gastroenterol Nutr 64:713–720CrossRefPubMedPubMedCentral

47.

Davidkova S, Prestidge TD, Reed PW, Kara T, Wong W, Prestidge C (2016) Comparison of reticulocyte hemoglobin equivalent with traditional markers of iron and erythropoiesis in pediatric dialysis. Pediatr Nephrol 31:819–826CrossRefPubMed

48.

Lopez-Ruzafa E, Vazquez-Lopez MA, Lendinez-Molinos F, Poveda-Gonzalez J, Galera-Martinez R, Bonillo-Perales A, Martin-Gonzalez M (2016) Reference values of reticulocyte hemoglobin content and their relation with other indicators of Iron status in healthy children. J Pediatr Hematol Oncol 38:e207–e212CrossRefPubMed

49.

Teixeira C, Barbot J, Freitas MI (2015) Reference values for reticulocyte parameters and hypochromic RBC in healthy children. Int J Lab Hematol 37:626–630CrossRefPubMed

50.

Locatelli F, Aljama P, Barany P, Canaud B, Carrera F, Eckardt KU, Horl WH, Macdougal IC, Macleod A, Wiecek A, Cameron S, European Best Practice Guidelines Working G (2004) Revised European best practice guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transplant 19(Suppl 2):ii1–i47PubMed

51.

Tessitore N, Solero GP, Lippi G, Bassi A, Faccini GB, Bedogna V, Gammaro L, Brocco G, Restivo G, Bernich P, Lupo A, Maschio G (2001) The role of iron status markers in predicting response to intravenous iron in haemodialysis patients on maintenance erythropoietin. Nephrol Dial Transplant 16:1416–1423CrossRefPubMed

52.

Thomas DW, Hinchliffe RF, Briggs C, Macdougall IC, Littlewood T, Cavill I, British Committee for Standards in H (2013) Guideline for the laboratory diagnosis of functional iron deficiency. Br J Haematol 161:639–648CrossRefPubMed

53.

Urrechaga E (2009) Clinical utility of the new Beckman-Coulter parameter red blood cell size factor in the study of erithropoiesis. Int J Lab Hematol 31:623–629CrossRefPubMed

54.

Kohgo Y, Niitsu Y, Kondo H, Kato J, Tsushima N, Sasaki K, Hirayama M, Numata T, Nishisato T, Urushizaki I (1987) Serum transferrin receptor as a new index of erythropoiesis. Blood 70:1955–1958PubMed

55.

Fernandez-Rodriguez AM, Guindeo-Casasus MC, Molero-Labarta T, Dominguez-Cabrera C, Hortal-Casc NL, Perez-Borges P, Vega-Diaz N, Saavedra-Santana P, Palop-Cubillo L (1999) Diagnosis of iron deficiency in chronic renal failure. Am J Kidney Dis 34:508–513CrossRefPubMed

56.

Chen YC, Hung SC, Tarng DC (2006) Association between transferrin receptor-ferritin index and conventional measures of iron responsiveness in hemodialysis patients. Am J Kidney Dis 47:1036–1044CrossRefPubMed

57.

Drakou A, Margeli A, Theodorakopoulou S, Agrogiannis I, Poziopoulos C, Papassotiriou I, Vlahakos DV (2016) Assessment of serum bioactive hepcidin-25, soluble transferrin receptor and their ratio in predialysis patients: correlation with the response to intravenous ferric carboxymaltose. Blood Cells Mol Dis 59:100–105CrossRefPubMed

58.

Lamola AA, Eisinger J, Blumberg WE (1980) Erythrocyte protoporphyrin/heme ratio by hematofluorometry. Clin Chem 26:677–678PubMed

59.

Garrett S, Worwood M (1994) Zinc protoporphyrin and iron-deficient erythropoiesis. Acta Haematol 91:21–25CrossRefPubMed

60.

Hastka J, Lasserre JJ, Schwarzbeck A, Strauch M, Hehlmann R (1993) Zinc protoporphyrin in anemia of chronic disorders. Blood 81:1200–1204PubMed

61.

Fishbane S, Lynn RI (1995) The utility of zinc protoporphyrin for predicting the need for intravenous iron therapy in hemodialysis patients. Am J Kidney Dis 25:426–432CrossRefPubMed

62.

Braun J, Hammerschmidt M, Schreiber M, Heidler R, Horl WH (1996) Is zinc protoporphyrin an indicator of iron-deficient erythropoiesis in maintenance haemodialysis patients? Nephrol Dial Transplant 11:492–497CrossRefPubMed

63.

Moreb J, Popovtzer MM, Friedlaender MM, Konijn AM, Hershko C (1983) Evaluation of iron status in patients on chronic hemodialysis: relative usefulness of bone marrow hemosiderin, serum ferritin, transferrin saturation, mean corpuscular volume and red cell protoporphyrin. Nephron 35:196–200CrossRefPubMed

64.

Wish JB (2006) Assessing iron status: beyond serum ferritin and transferrin saturation. Clin J Am Soc Nephrol 1(Suppl 1):S4–S8CrossRefPubMed

65.

Ozment CP, Turi JL (2009) Iron overload following red blood cell transfusion and its impact on disease severity. Biochim Biophys Acta 1790:694–701CrossRefPubMed

Title: Measurement of iron status in chronic kidney disease
Author: Wesley Hayes
Publication date: 01-04-2019
Publisher: Springer Berlin Heidelberg
Published in: Pediatric Nephrology / Issue 4/2019
Print ISSN: 0931-041X
Electronic ISSN: 1432-198X
DOI: https://doi.org/10.1007/s00467-018-3955-x

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Measurement of iron status in chronic kidney disease

Abstract

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2019

Childhood onset steroid-sensitive nephrotic syndrome continues into adulthood

Renal phosphate handling and inherited disorders of phosphate reabsorption: an update

CoenzymeQ10 therapy in two sisters with CoQ6 mutations with long-term follow-up

Correction to: Eculizumab in atypical hemolytic uremic syndrome: strategies toward restrictive use

Correction to: An open-label, single-dose study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of cinacalcet in pediatric subjects aged 28 days to < 6 years with chronic kidney disease receiving dialysis

Equations to estimate prednisone dose using body weight